Gelderblom H, Verweij J, Nooter K, Sparreboom A (September 2001). "Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation". European Journal of Cancer. 37 (13): 1590–1598. doi:10.1016/S0959-8049(01)00171-X. PMID11527683.
Ottaggio L, Bestoso F, Armirotti A, Balbi A, Damonte G, Mazzei M, et al. (January 2008). "Taxanes from Shells and Leaves of Corylus avellana". Journal of Natural Products. 71 (1): 58–60. doi:10.1021/np0704046. PMID18163585.
Jordan MA, Wilson L (April 2004). "Microtubules as a target for anticancer drugs". Nature Reviews. Cancer. 4 (4): 253–265. doi:10.1038/nrc1317. PMID15057285. S2CID10228718.
Howat S, Park B, Oh IS, Jin YW, Lee EK, Loake GJ (May 2014). "Paclitaxel: biosynthesis, production and future prospects". New Biotechnology. 31 (3): 242–245. doi:10.1016/j.nbt.2014.02.010. PMID24614567.
Hall N (March 2003). "Creating complexity--the beauty and logic of synthesis". Chemical Communications (6): 661–664. doi:10.1039/b212248k. PMID12703766.
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (May 1971). "Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia". Journal of the American Chemical Society. 93 (9): 2325–2327. doi:10.1021/ja00738a045. PMID5553076.
Kachooei E, Moosavi-Movahedi AA, Khodagholi F, Mozaffarian F, Sadeghi P, Hadi-Alijanvand H, et al. (June 2014). "Inhibition study on insulin fibrillation and cytotoxicity by paclitaxel". Journal of Biochemistry. 155 (6): 361–373. doi:10.1093/jb/mvu012. PMID24535601.
Moscarello MA, Mak B, Nguyen TA, Wood DD, Mastronardi F, Ludwin SK (April 2002). "Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination". Multiple Sclerosis. 8 (2): 130–138. doi:10.1191/1352458502ms776oa. PMID11990870. S2CID45994154.
Musse AA, Polverini E, Raijmakers R, Harauz G (October 2008). "Kinetics of human peptidylarginine deiminase 2 (hPAD2)--reduction of Ca2+ dependence by phospholipids and assessment of proposed inhibition by paclitaxel side chains". Biochemistry and Cell Biology. 86 (5): 437–447. doi:10.1139/o08-124. PMID18923545.
"Naveruclif EPAR". European Medicines Agency (EMA). 9 November 2023. Retrieved 28 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Apexelsin EPAR". European Medicines Agency. 30 May 2024. Retrieved 31 May 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
Gelderblom H, Verweij J, Nooter K, Sparreboom A (September 2001). "Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation". European Journal of Cancer. 37 (13): 1590–1598. doi:10.1016/S0959-8049(01)00171-X. PMID11527683.
Ottaggio L, Bestoso F, Armirotti A, Balbi A, Damonte G, Mazzei M, et al. (January 2008). "Taxanes from Shells and Leaves of Corylus avellana". Journal of Natural Products. 71 (1): 58–60. doi:10.1021/np0704046. PMID18163585.
Jordan MA, Wilson L (April 2004). "Microtubules as a target for anticancer drugs". Nature Reviews. Cancer. 4 (4): 253–265. doi:10.1038/nrc1317. PMID15057285. S2CID10228718.
Staniek A, Woerdenbag HJ, Kayser O (December 2009). "Taxomyces andreanae: a presumed paclitaxel producer demystified?". Planta Medica. 75 (15): 1561–1566. doi:10.1055/s-0029-1186181. PMID19809969. S2CID260283080.
Howat S, Park B, Oh IS, Jin YW, Lee EK, Loake GJ (May 2014). "Paclitaxel: biosynthesis, production and future prospects". New Biotechnology. 31 (3): 242–245. doi:10.1016/j.nbt.2014.02.010. PMID24614567.
Hall N (March 2003). "Creating complexity--the beauty and logic of synthesis". Chemical Communications (6): 661–664. doi:10.1039/b212248k. PMID12703766.
Wall ME, Wani MC (February 1995). "Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture". Cancer Research. 55 (4): 753–760. PMID7850785.
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (May 1971). "Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia". Journal of the American Chemical Society. 93 (9): 2325–2327. doi:10.1021/ja00738a045. PMID5553076.
Fuchs DA, Johnson RK (August 1978). "Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison". Cancer Treatment Reports. 62 (8): 1219–1222. PMID688258.
Kachooei E, Moosavi-Movahedi AA, Khodagholi F, Mozaffarian F, Sadeghi P, Hadi-Alijanvand H, et al. (June 2014). "Inhibition study on insulin fibrillation and cytotoxicity by paclitaxel". Journal of Biochemistry. 155 (6): 361–373. doi:10.1093/jb/mvu012. PMID24535601.
Moscarello MA, Mak B, Nguyen TA, Wood DD, Mastronardi F, Ludwin SK (April 2002). "Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination". Multiple Sclerosis. 8 (2): 130–138. doi:10.1191/1352458502ms776oa. PMID11990870. S2CID45994154.
Musse AA, Polverini E, Raijmakers R, Harauz G (October 2008). "Kinetics of human peptidylarginine deiminase 2 (hPAD2)--reduction of Ca2+ dependence by phospholipids and assessment of proposed inhibition by paclitaxel side chains". Biochemistry and Cell Biology. 86 (5): 437–447. doi:10.1139/o08-124. PMID18923545.
Jordan MA, Wilson L (April 2004). "Microtubules as a target for anticancer drugs". Nature Reviews. Cancer. 4 (4): 253–265. doi:10.1038/nrc1317. PMID15057285. S2CID10228718.
Staniek A, Woerdenbag HJ, Kayser O (December 2009). "Taxomyces andreanae: a presumed paclitaxel producer demystified?". Planta Medica. 75 (15): 1561–1566. doi:10.1055/s-0029-1186181. PMID19809969. S2CID260283080.